Drugs & Targets Exkivity gets FDA accelerated approval for metastatic NSCLC with EGFR exon 20 insertion mutations September 17, 2021Vol.47 No.34
Drugs & Targets Active ingredient hypericin receives FDA orphan drug designation for T-cell lymphoma September 10, 2021Vol.47 No.33
Drugs & Targets Science 37, Foundation Medicine collaborate on interventional home-based clinical trials in oncology September 10, 2021Vol.47 No.33
Drugs & Targets FDA requires monitoring of long-term clinical outcomes for robotic surgery in breast cancer September 03, 2021Vol.47 No.32
Drugs & Targets Tibsovo receives FDA approval for advanced or metastatic cholangiocarcinoma September 03, 2021Vol.47 No.32
Drugs & Targets Opdivo receives FDA approval for adjuvant treatment of urothelial carcinoma September 03, 2021Vol.47 No.32
Drugs & Targets Jemperli receives FDA accelerated approval for dMMR advanced solid tumors September 03, 2021Vol.47 No.32
Drugs & Targets Welireg receives FDA approval in indication for adults with VHL September 03, 2021Vol.47 No.32
Drugs & Targets Keytruda + Lenvima combination receives FDA approval for frontline advanced RCC September 03, 2021Vol.47 No.32
